The results from clinical studies (NCT00836654) demonstrated that the application of catumaxomab is associated with the depletion of CD133+/EpCAM+ CSCs from malignant ascites in patients with the ovarian, pancreatic, and gastric cancer [134]. Here, PROM1 is linked to gastric cancer.